Hledání v detailu akcií
Top akcie
NázevNávštěvy
31 150
1 248
1 134
1 034
932
677
543
518
373
365
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,77
KB1,26
PKN105,8106,251,00
Msft84,6384,64-0,82
IBM153,93153,97-0,54
DCX70,9770,99-0,15
PFE36,4336,441,93
14.12.2017 20:37:47
Indexy online
AD Index online
select
AD Index online
 

  • 14.12.2017 20:37:24
Egalet (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,9937 -2,58 -0,03 312 695
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.12.2017
Popis společnosti
Obecné informace
Název společnostiEgalet Corp
TickerEGLT
Kmenové akcie:Ordinary Shares
RICEGLT.O
ISINUS28226B1044
Prioritní akcieConv. Pref. Shrs Series A-1
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs Series B
Prioritní akcieConv. Pref. Shrs Series B-1
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2016 154
Akcie v oběhu k 8.11.2017 43 029 615
Počet akcionářů k 31.12.2016 31
MěnaUSD
Kontaktní informace
Ulice600 Lee Rd Ste 100
MěstoWAYNE
PSČ19087-5624
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 108 334 200
Fax13026555049

Business Summary: Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Egalet Corp revenues increased 69% to $18.3M. Net loss increased 2% to $70.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 41% to $27M (expense), Interest (income) expense increase of 70% to $14M (expense), General and administrative increase of 27% to $24M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 14.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardTimothy Walbert5015.6.201515.6.2015
President, Chief Executive Officer, DirectorRobert Radie52
Chief Financial Officer, Executive Vice President, SecretaryStanley Musial55
Chief Operating Officer, Executive Vice PresidentMark Strobeck45
Senior Vice President, General CounselPaul Varki-16.11.201516.11.2015
Senior Vice President - CommunicationsE. Blair Clark-Schoeb-
Senior Vice President - Research & DevelopmentKarsten Lindhardt44
Chief Accounting OfficerBarbara Carlin411.1.20161.1.2016
Chief Medical OfficerJeffrey Dayno5931.7.201431.7.2014
Chief Commercial OfficerPatrick Shea-19.9.201619.9.2016